Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,024 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04339062 | Cemiplimab in AlloSCT/SOT Recipients With CSCC(CONTRAC) | completed | Phase 1 / Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT04752384 | Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients | completed | Phase 2 | 20 | Medical College of WisconsinOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT03602911 | A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients | completed | Phase 2 | 20 | West Virginia UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT03721757 | CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer(NICO) | completed | Phase 2 | 21 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04710498 | Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 20 | Stanford UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04732494 | Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(AdvanTIG-203) | completed | Phase 2 | 125 | BeiGeneINDUSTRY | 6 | Jan 31, 2025 | clinicaltrials |
| NCT03715946 | Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | completed | Phase 2 | 40 | Robert L. Ferris, MD, PhDOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04649476 | Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma(NEOPBOSCC) | completed | Phase 2 | 68 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT03719924 | Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma(OESIRI) | completed | Phase 2 | 106 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT04815720 | Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(KEYNOTE-B84) | completed | Phase 1 / Phase 2 | 49 | Vaccinex Inc.INDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT02281955 | De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study | completed | Phase 2 | 115 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05007613 | Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 24 | National Taiwan University HospitalOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT02573493 | Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)(APA) | completed | Phase 2 | 96 | Washington University School of MedicineOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03946358 | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)(VolATIL) | completed | Phase 2 | 47 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04212598 | The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer | completed | Phase 2 | 40 | Wuhan UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT05060471 | PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients | completed | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03487549 | Cantharidin and Occlusion in Verruca Epithelium(COVE-1) | completed | Phase 2 | 56 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT02538510 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT02647125 | A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC | completed | Phase 2 | 126 | Fudan UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT03878979 | Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT02844075 | Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29) | completed | Phase 2 | 28 | Yonsei UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06691503 | A Clinical Trial of Esophagectomy for Esophageal Carcinoma | completed | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT01530997 | De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca | completed | Phase 2 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT03985046 | Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC | completed | Phase 2 | 75 | Fudan UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04144517 | A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer | completed | Phase 2 | 14 | Mural Oncology, IncINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT03714828 | Study of TVEC in Patients With Cutaneous Squamous Cell Cancer | completed | Phase 2 | 11 | University of ArizonaOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05896215 | OM202JP Clinical Study of KNP2002 | completed | Phase 2 | 159 | KinoPharma Inc.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT02264210 | Icotinib for Completed Resected IB NSCLC With EGFR Mutation(CORIN) | completed | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT02258659 | Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer(OPTIMA) | completed | Phase 2 | 62 | University of ChicagoOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT03521570 | Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer | completed | Phase 2 | 62 | Emory UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04721223 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 12 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03422536 | Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of ArizonaOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT03284424 | Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629) | completed | Phase 2 | 159 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Aug 23, 2024 | clinicaltrials |
| NCT02777385 | Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer | completed | Phase 2 | 80 | Dan ZandbergOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT01064479 | Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02383927 | Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations | completed | Phase 2 | 63 | Kura Oncology, Inc.INDUSTRY | 10 | Jul 11, 2024 | clinicaltrials |
| NCT04839471 | BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)(BEAR) | completed | Phase 2 | 49 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT04435197 | Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma(PALACE-2) | completed | Phase 2 | 143 | Ruijin HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT01581840 | Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus | completed | Phase 1 / Phase 2 | 45 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT04541355 | Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin | completed | Phase 2 | 16 | Hyunseok Kang, MDOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02964559 | Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer | completed | Phase 2 | 11 | Emory UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03719690 | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy(AIM-HN/SEQ-HN) | completed | Phase 2 | 296 | Kura Oncology, Inc.INDUSTRY | 16 | Jun 21, 2024 | clinicaltrials |
| NCT02923258 | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | completed | Phase 2 / Phase 3 | 224 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT04107103 | Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma(NivoPlus) | completed | Phase 2 | 6 | AHS Cancer Control AlbertaOTHER | 1 | Jun 14, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Apr 23, 2025source: clinicaltrials